Skip to main content
. Author manuscript; available in PMC: 2015 Feb 25.
Published in final edited form as: Ann Neurol. 2014 Feb 25;75(2):317–323. doi: 10.1002/ana.24083

Figure 1. Clinical course, treatment, and CSF/serum NMDAR antibody titers in four patients with neurological relapses post-HSE.

Figure 1

Scaling of X-axes is different in all patients reflecting length of follow-up. Broken x-axis represents discontinuous axis and change of tick interval. Right y-axis and grey curve: quantitative measure of disease severity Pediatric Cerebral Performance Category, PCPC14(1=normal,2=mild disability, 3=moderate disability, 4=severe disability, 5= coma or vegetative state, 6=dead). Left y-axis: filled boxes NMDAR antibody titer in CSF, empty diamonds NMDAR antibody titer in serum (multiplied x100 to fit the same axis as CSF). Camera symbol represent available video segments in the supplementary video. IVIg: intravenous immunoglobulins, IvMP: intravenous methylprednisolone, or steroids: oral steroids, Ritux: rituximab, CycP: cyclophosphamide.